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KESAN AFLATOKSIN B1 DAN OCHRATOKSIN A PADA SEL KANSER 
PAYUDARA  
 
 
ABSTRAK 
Pencemaran mikotoksin di dalam komoditi makanan yang disebabkan oleh 
kulat seperti Aspergillus dan Penicillium adalah perkara biasa di negara-negara yang 
mempunyai cuaca tropika seperti Malaysia kerana keadaan ini dapat mengekalkan 
pertumbuhan dan perkembangan fungus tersebut. Mikotoksin dilaporkan boleh 
menyebabkan keracunan makanan yang teruk, kerosakan hati dan terbukti 
karsinogenik pada sel-sel buah pinggang dan hati. Sifat karsinogen Aflatoxin B1 dan 
Ochratoxin dapat meningkatkan risiko kanser payudara dan kajian molekular perlu 
dilakukan untuk mengesahkannya. Objektif kajian ini adalah untuk mengkaji kesan 
AB1 dan OTA terhadap aktiviti kesitotoksikan sel, ekspresi gen yang berkaitan 
dengan tumor dan peningkatan sel-sel kanser payudara di kepekatan yang rendah dan 
tinggi. Stok larutan 100 μg/mLAflatoxin B1 dan Ochratoxin A telah disediakan 
menggunakan DMSO sebagai pelarut dan AB1 dengan kepekatan 1.2 μg/mL dan 
OTA dengan kepekatan 3.4 μg/mLdigunakan untuk merawat MCF7. Di samping itu, 
AB1 dengan kepekatan 2.3 μg/mLdan OTA dengan kepekatan 5.7 μg/mLdigunakan 
untuk merawat sel MCF10A. Sel-sel dibiakkan dalam ketumpatan 0.3x10
6
 dan 
apabila sel mencapai 90% konfluensi, sel-sel telah dirawat dan diinkubasi selama 48 
jam untuk melaksanakan prosedur- prosedur seperti sitotoksik XTT, morfologi dan 
penghijrahan sel, kitaran sel, apoptosis dan spesis oksigen reaktif. Di samping itu, 
anotasi gen dan kuantifikasi ekspresi gen menggunakan RT-qPCR dijalankan untuk 
menyiasat urutan gen berkaitan tumor di kedua-dua jenis sel. Di samping itu, p53 di 
dalam sel MCF10A dan cMyc di dalam sel MCF7 telah diubah menggunakan siRNA 
 xxviii 
dan RT-qPCR digunakan untuk menentukan kuantiti gen-gen tumor tersebut setelah 
diubah dan dirawat (sebelum/selepas) dengan AB1 dan OTA. Akhirnya, kepekatan 
AB1 dan OTA yang tinggi digunakan untuk merawat sel-sel MCF7 dan MCF0A dan 
implikasi terhadap daya tahan sel terhadap kepekatan toksin yang tinggi dan tahap 
ROS disiasat. Rawatan MCF7 (kepekatan AB1 1.2μg / mLdan OTA dengan 
kepekatan 3.4μg / ml) dan MCF10A (dengan kepekatan AB1 2.3μg / mLdan OTA 
dengan kepekatan 5.7μg / ml) menunjukkan perubahan ketara dalam ekspresi gen 
tumor yang berkaitan di dalam sel MCF7 dan MCF10A dan seterusnya menyebabkan 
kerosakan DNA, menahan kitaran sel, meningkatkan pergerakan dan meningkatkan 
saiz sel. AB1 dan OTA meningkatkan keagresifan MCF7 dan meningkatkan risiko 
dalam meningkatkan tumor dalam MCF10A. 
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THE IMPLICATION OF AFLATOXIN B1 AND OCHRATOXIN A 
EXPOSURE ON TUMOR RELATED GENES IN NORMAL AND 
CANCEROUS BREAST CELLS 
 
 
 
ABSTRACT  
Mycotoxin contamination of food commodities caused by fungal strains such 
as Aspergillus and Penicillium is common in countries with tropical weather such as 
Malaysia due to the conditions that sustains their growth and development. 
Mycotoxins have been reported to cause severe food poisoning, liver damage and 
were proven carcinogenic to kidney and liver cells. The carcinogenic nature of 
Aflatoxin B1 and Ochratoxin A could increase the risks of breast cancer and an 
investigation on a molecular level need to be carried out to confirms it. The 
objectives of this study are to investigate the effect of AB1 and OTA on cell 
activities cytotoxicity, tumor related genes expression and the proliferation of breast 
cancer cells at a low and a high concentration. Stock solutions of 100 ug/mL of 
Aflatoxin B1 and Ochratoxin A were prepared using DMSO as a solvent and AB1 in 
final concentration of 1.2 µg/mL and OTA in final concentration 3.4 µg/mL were 
used to treat MCF7. In addition to that, AB1 in final concentration of 2.3 µg/mL and 
OTA in final concentration 5.7 µg/mL were used to treat MCF10A cell. Cells were 
seeded in the density of 0.3 x 10
6 
and once 90% confluent, cells were treated and 
incubated for 48 hours to perform XTT (2H-Tetrazolium, 2,3-bis(2-methoxy-4-nitro-
5-sulfophenyl)-5-[(phenylamino)carbonyl]-hydroxide) cytotoxicity assay, cell 
morphology and cell migration assay, cell cycle assay, apoptosis assay and reactive 
oxygen species assay. In addition to that, gene annotation and quantification of gene 
 xxx 
 
expression using RT-qPCR was carried out to investigate the expression of tumor 
related genes in both cell lines post treatment. Next to that, p53 in MCF10A and 
cMyc in MCF7 were knocked down using siRNA and gene expression of tumor 
related genes after the knockdown and (pre/post) treatment with AB1 and OTA was 
quantified using RT-qPCR. Finally, high concentration of AB1 and OTA were used 
to treat MCF7 and MCF10A cells and the implication of these high concentrations on 
cell viability and ROS levels were investigated. Treating MCF7 (AB1 final 
concentration of 1.2 µg/mL and OTA in final concentration 3.4 µg/ml) and MCF10A 
(AB1 final concentration of 2.3 µg/mL and OTA in final concentration 5.7 µg/ml) 
showed a significant change in gene expression of tumor related genes in MCF7 and 
MCF10A and that in turn caused DNA damage, cell cycle arrest, increased motility 
and increase cell size. Result showed that AB1 and OTA increase the invasiveness of 
MCF7 and increase the risk in developing tumorigenicity in MCF10A.    
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CHAPTER 1 : INTRODUCTION  
1.1 Overview  
Breast cancer is the most common cause of death to women worldwide. 
Approximately 1 in 20 women in this country reported develop breast cancer (Yip, 
Taib and Mohamed, 2006). Genetics factors due to mutations of BRCA1 and BRCA2 
are well known causes of breast cancer (Venkitaraman, 2001). The alteration p53 
gene in breast carcinomas and highly expressed of HER1 (Human epidermal growth 
factor receptor 1), HER2 (human epidermal growth factor receptor 2) and the c-Myc 
(Myelocytomatosis viral oncogene) oncogenes that leads to the synthesis of new 
protein also enhanced the activation of oncogenes. Mycotoxins have been reported to 
influence breast tumor suppressor genes p53 (Tumor protein 53), BRCA1 (Breast 
cancer 1) and BRCA2 (Breast cancer 2), the human oncogenes HER1, HER2 and c-
Myc. Moreover, mycotoxins may inhibit the proliferation of cells, protein synthesis 
and initiating apoptosis. Aflatoxin B1 and Ochratoxin A are the most dangerous 
mycotoxins for their lethal affect to human and animal (El Golli-Bennour et al., 
2010). Aflatoxin B1 has been reported as the highest carcinogenicity among all 
mycotoxins capable of penetrating cell membrane and attaches to its DNA where it 
makes changes to the genome or causes irreversible mutations to become more stable 
(Smela et al., 2001). Ochratoxin A involved in covalent DNA adduction and 
involved in oxidative DNA damage and considered as genotoxic carcinogen because 
of their ability to oxidase DNA lesions and the direct DNA adducts through Quinone 
formation (Liu et al., 2012). Therefore, further study needs to be carried out to 
determine the effect of these mycotoxins on cancerous cells based on their ability to 
either kill or causes the breast cancer.  
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To achieve this, cytotoxicity, cell morphology and migration, cell cycle and 
reactive oxygen species (ROS) levels detection assays were conducted to investigate 
the toxic effect of these toxins on MCF7 and MCF10A. The interest of connecting 
mycotoxins contamination to the occurrence or the increase in the risk of breast 
cancer required the study of these toxins on normal and cancerous breast cells and 
since working with primary cells was hard to sustain, the use of MCF7 and MCF10A 
was the best option. Both MCF7 and MCF10A represent the best model to study 
normal and cancer breast cells in vitro (Simstein et al., 2003; Kenny et al., 2007) and 
they were used extensively in many researched and due to that these cells were 
selected. The use of these cells in this study was due to the face that one of the risk 
facto of  In addition to that, the quantification of tumor suppressing genes (BRCA1, 
BRCA2 and p53), oncogenes (HER1, HER2 and cMyc), cell cycle genes CCND1 
(Cyclin D1), WNT3A (Wingless-related integration site), MAPK1 (Mitogen-
Activated Protein Kinase) and MAPK3 (Mitogen-Activated Protein Kinase 3)  and 
apoptosis genes BCL2 (B-cell lymphoma 2), MCL1 (Myeloid cell leukemia 1), 
DAPK1 (Death-associated protein kinase 1), Casp8 (Cysteine-aspartic acid protease 
8) and Casp9 (Cysteine-aspartic acid protease 9) gene expression in both immortalize 
and cancerous cells was conducted by using RT-qPCR. Finally, the cancerous and 
immortalized cells will be treated with high concentration of AB1 OTA to induce 
apoptosis and further investigate the morphological and the molecular changes of the 
cells. Next to that, this study conducted gene annotation to understand the regulation 
of gene expression upon treatment by comparing it with well-established biological 
pathways. Finally, gene knockdown of cMyc in MCF7 cells and treatment with AB1, 
knockdown of p53 in MCF10A cells and treatment with OTA was conducted and the 
implication of knocking down these genes and treating the cells with the respective 
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toxins on different tumor suppressing genes and oncogenes. The understanding of the 
regulation of these mycotoxins on normal and cancer breast cells may lead to new 
knowledge of prevention and awareness in human kind. 
1.2 Hypothesis  
Many chemical and physical mutagens were proved to cause mutation and 
inactivation of the cancer suppressor genes such as p53, BRCA1 and BRCA2 and the 
activation of the oncogenes such as HER-1, HER-2 and the cMyc. Some of the 
important chemical compounds that could cause a mutation in these genes included 
mycotoxins. Mycotoxins are carcinogenic toxins that are produced by many 
Aspergillus and Penicillium species growing on food commodities. Therefore, this 
study hypothesized that there was impact of mycotoxins such as aflatoxins and 
ochratoxins on the regulation of breast cancer cells p53, BRCA1, BRCA2, HER-1, 
HER-2 and cMyc and alter cell growth and might initiate apoptosis. 
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1.3 General objective  
The main aim of this study was to assist the effect of Aflatoxin B1 and 
Ochratoxin A in increasing the risk of developing breast cancer by influencing the 
gene expression of tumor related genes.  
1.4 Objectives 
The objectives in this study include: 
 To investigate the effect of AB1 and OTA on cell activities of MCF7 and 
MCF10A.   
 To investigate the effect of AB1 and OTA on gene expression of tumor 
suppressing genes (BRCA1, BRCA2 and p53), oncogenes (HER1, HER2 and 
cMyc), cell cycle genes (CCND1, WNT3A, MAPK1 and MAPK3) and apoptosis 
genes (BCL2, MCL1, DAPK1, Casp8 and Casp9) in MCF7 and MCF10A.  
 To investigate the effect of AB1 and OTA on tumor suppressing genes 
(BRCA1, BRCA2 and p53), and oncogenes (HER1, HER2 and cMyc) in MCF7 
with knocked down cMyc and in MCF10A with knocked down p53 and to 
investigate the mechanisms regulated by aflatoxin B1 and ochratoxin A on 
the proliferation of the breast cancer cells. 
 To investigate the implication of high and uniformed concentration of AB1 
and OTA in MCF7 and MCF10A. 
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1.5 Study flow chart  
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CHAPTER 2 : LITERATURE REVIEW  
2.1 Mycotoxins 
Mycotoxins can be defined as carcinogenic toxins that produced by many 
fungal species such as Aspergillus and Penicillium that can grow easily on food 
commodities where they produce these toxins as secondary metabolites (Turner, 
Subrahmanyam and Piletsky, 2009). There are several mycotoxins discovered up to 
date but among all of them, aflatoxin B1 has been distinguished as the strongest 
carcinogenic mycotoxin (C. Renzulli et al., 2004; Nguyen et al., 2007; Villa and 
Markaki, 2009). Aflatoxin B1 capable of penetrating the cell membrane and combine 
with cellular DNA where it can cause damage and mutations (Adam et al., 2017). 
The ability of mycotoxins to move across the cell membrane was due to its chemical 
nature that makes mycotoxins highly liposoluble compounds that can be absorbed 
from the most common sites of exposure like gastrointestinal and respiratory tract 
and eventually it can reach the bloodstream and dissimilate throughout the body 
(Godfrey et al., 2013). There are many portals of exposure to these toxins and that 
include ingestion of the contaminated food, drinking contaminated water, direct 
contact with the skin and (Godfrey et al., 2013). The action of mycotoxin inside the 
cell cytoplasm usually takes place by the action of cytochrome P450 which 
metabolize mycotoxins to mycotoxin-8, 9-epoxide through detoxification metabolic 
pathway. These mycotoxin-8, 9-epoxide are highly reactive and unstable so they tend 
to attach themselves to more stable cellular components such as DNA or protein to 
regain their stability (Godfrey et al., 2013). In the case of Aflatoxin B1, one of the 
strongest oncogenes, metabolization of that toxin will produce aflatoxin-8, 9-epoxide 
will bind to the DNA molecule with enormous affinity forming aflatoxin-N7-guanine 
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which cause a transmutation in the DNA molecule where guanine (G) with me 
transverse to thymine (T). This type of mutation would lead to altering cell cycle by 
affecting the activation of p53 genes and inhibiting the production of Tp53, an 
essential protein for the control of tumor progression and development (Ricordy et 
al., 2002; Bbosa et al., 2013; Adam et al., 2017).  
2.1.1 Mycotoxins and their natural habitats  
In an experiment conducted by El-Banna and colleagues (El-Banna, Pitt and 
Leistner, 1987) 1400 Penicillium species and isolates were collected from different 
cultures and sources and some of them were even isolated from food, food 
commodities, and animal feed. Each isolate was identified by the help of Pitt's 
classification to determine their mycotoxins production and from this study, more 
than 18 different mycotoxins were isolated. For the extraction of the different 
mycotoxins, each of the isolates was grown on malt extract agar and cultures were 
incubated for one to three weeks at room temperature. Once the fungal growth reach 
maximum and mycotoxins concentration in the media become high, mycotoxins 
were extracted by chloroform and mycotoxins were concentrated and finally they 
were classified and characterized by TLC (van der Gaag et al., 2003). The result of 
this experiment was outstanding and a total of 18 mycotoxins where classified and 
identified from several Penicillium species namely: Citreoviridin, Brevianamid A, 
Fumitremorgin B, Citrinin, Cyclopiazonic acid, luteoskyrin, Griseofulvin, 
Ochratoxin A, Patulin, Penicillic acid, PR-toxin, Penitrem A, Verrucosidin, 
Verruculogen, Xanthomegnin, Roquefortine, Rugulosin and finally Viridicarumtoxin 
(El-Banna, Pitt and Leistner, 1987; Pitt and Hocking, 2009).  
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According to Kozakiewicz and colleagues, an additional important group of 
highly carcinogenic mycotoxins was found to be produced by Aspergillus species 
and they are called Aflatoxins (Pitt and Hocking, 2009).  Aflatoxins are mainly 
produced by the fungi Aspergillus Flavus and Aspergillus Parasiticus and its 
carcinogenicity and its involvement in cancer was studies and confirmed by many 
studies (Smela et al., 2001; Cui et al., 2015; Kim et al., 2016; Zeng et al., 2016). 
Aflatoxins are classified based on the producing organism, Aspergillus Flavus will 
produce Aflatoxin B1 & B2, and Aspergillus parasiticus will produce Aflatoxin G1 
& G2 (Turner, Subrahmanyam and Piletsky, 2009; S.-P. Zhao et al., 2016) and 
researchers indicated that Aflatoxin B1 and G1 are the most carcinogenic and were 
reported in many human and animal diseases and cancers. Aflatoxin contamination 
can be found largely in food and feed products such as cereal such as maize, 
sorghum, pearl millet, rice, and wheat. Another group of food was the oilseeds that 
include groundnut, soybean, sunflower, and cotton. Additionally, research showed 
that even spices such as chilies, black pepper, coriander, turmeric, and zinger can be 
contaminated by aflatoxins. Another group of food that can be easily contaminated 
by aflatoxin was the tree nuts such as almonds, pistachio, walnuts, and coconut and 
aflatoxin contamination was reported many times in milk and dairy products 
(Rasooly et al., 2013; Mohd Azaman et al., 2015; Nierman et al., 2015; Prakash et 
al., 2015; Gizachew et al., 2016; Ngoma et al., 2017; Singh and Cotty, 2017). Recent 
findings showed that aflatoxins can also contaminate tobacco leaves (Kedia et al., 
2015; Zitomer et al., 2015; Qi et al., 2017) and it can also be present in dry soil 
(Ortega-Beltran, Jaime and Cotty, 2015; Starr, Rushing and Selim, 2017; Thathana et 
al., 2017; Pereyra et al., 2018) and the underground water (Oliveira et al., 2016). 
Aflatoxin B was reported to contaminate milk and dairy products and many 
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techniques were developed to accomplish that. Some of the effective methods to 
reduce Aflatoxin B1 includes heat and irradiations but the most effective method 
reported was treatment with bisulfate, strong acids and bases. In milk, Aflatoxin B1 
was reduced by treating milk with Hydrogen peroxide and riboflavin (Kabak et al., 
2006; Bhat et al., 2010; Afsah-Hejri et al., 2013). 
Ochratoxin was found to be as important and as dangerous as Aflatoxin group 
(Heussner and Bingle, 2015). According to the studies performed on Ochratoxins, 
the mode of action and how they affect humans and animals are similar to Aflatoxin 
(Li et al., 2012; Hibi et al., 2013; Ahmed, 2015). The main producer of Ochratoxins 
was Aspergillus species namely Aspergillus Ochraceus and Aspergillus Niger in 
addition to some Penicillium species namely Penicillium Verrucosum and 
Penicillium Carbonarius (El Golli-Bennour et al., 2010). Among all types, 
Ochratoxin A was widely studied due to the high degree of carcinogenicity (Khatoon 
et al., 2018) and usually, it was found in the food commodities favored by 
Aspergillus and Penicillium species such as coffee, dried fruit, and cereals (Cabañes 
and Bragulat, 2018).  
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2.1.2 Nature of mycotoxins (physical and chemical) 
Among the different mycotoxins, it was reported that the most important 
mycotoxins are Aflatoxin B1 and Ochratoxin A (El Golli-Bennour et al., 2010) and 
normally, both toxin co-exist in the same habitat (Nguyen et al., 2007; Bircan, 2009; 
El Golli-Bennour et al., 2010). 
2.1.2(a) Aflatoxin B1 
 
Figure 2.1: Chemical structure of Aflatoxin B1 (Bennett, Klich and Mycotoxins, 
2003) 
 
Aflatoxins were reported to be the most important mycotoxins and they ate 
produced mainly by A. flavus and A. parasiticus (Mokbel and Alharbi, 2015). Up to 
date, there are four types of aflatoxins known namely B1, B2, G1, and G2 and these 
types are classified based on the colour the omit under the UV light, either green or 
blue and their movement in thin layer chromatography (TLC) (Zhang, Liu and Chen, 
2005; Li et al., 2015; Qi et al., 2017). The chemical composition of the aflatoxin was 
presented as C17H12O6 (Wei et al., 2017) mentioned in Figure 2.1. The biosynthesis 
of aflatoxins takes place by first the production of norsolorinic acid, anthraquinone 
precursor, and these precursors will join by the action of polyketide synthase. Next, 
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to that, there will be 15 post polyketide synthase steps which will result in yielding a 
series of toxigenic metabolites (Conradt et al., 2015).  
 
2.1.2(b) Ochratoxin A 
 
Figure 2.2: Chemical structure of Ochratoxin A (Bennett, Klich and 
Mycotoxins, 2003) 
Along with Aflatoxin B1 and Ochratoxin A were considered to be the most 
important mycotoxin for their ability to induce mutation, altering cell growth and 
induce cell arrest, imitate apoptosis and cause kidney cancer (O’Brien and Dietrich, 
2005; Rached et al., 2006; Kim et al., 2016). Ochratoxin A categorized as one of the 
Ochratoxin group of mycotoxins and produced by Aspergillus ochraceous  (Z. Y. 
Zhao et al., 2016) and chemically presented as C20H18ClNO6 (Santoro et al., 2017) 
mentioned in Figure 2.2.  
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Due to mycotoxins chemical composition, they are reposted to be strong and 
heat stable which makes it very difficult and sometimes impossible to completely 
neutralize them during food processing procedure and sterilization and their 
contamination in food will eventually entered the human biological system 
(Bullerman and Bianchini, 2007; Kabak, 2009). The heat stability of mycotoxins was 
due to the presence heterocyclic, oxygen-containing bisdifuran ring system (Iram et 
al., 2016) that make these toxins withstand high heat. From the structure of Aflatoxin 
B1 and Ochratoxin A described in Figure 2.1 and 2.2, we can see that both AB1 and 
OTA have 2 rings in which six carbon atoms are attached together and each carbon 
atom with a hydrogen atom attached to it in a perfectly regular hexagon that has 
single and double bonds distributed evenly around the ring structure and this 
structure was responsible for their thermal and chemical stability (Manahan, 2002; 
Tomašević-Čanović et al., 2003; Weiss et al., 2003; Yiannikouris et al., 2006; Siegel 
et al., 2010). Mycotoxins stability prevent most of them from being eliminated or 
destroyed by different sterilization protocols and that make them a very common 
contaminant in food and feed (Bhat, Rai and Karim, 2010; el Khoury and Atoui, 
2010; Afsah-Hejri et al., 2013; Nierman et al., 2015; Gizachew et al., 2016) which 
eventually reach the biological system of human and animals. Many researchers 
relate the chemical composition and the physical nature of mycotoxins to their 
carcinogenicity as many of them were reported in several cancers around the globe 
and that makes these toxins even more dangerous and hazardous (Pfohl-Leszkowicz 
and Manderville, 2007; Kim et al., 2016; Adam et al., 2017).   
Many researchers conclude that the most mycotoxins found in cereals or 
grains are Fumonisins,  Aflatoxins, Zearalenone, Ochratoxin A and Deoxynivalenol 
(Visconti and Pascale, 2010). Many food processes are reported to effect mycotoxins 
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and these include cleaning, cooking, roasting, canning, alkaline cooking, baking, 
frying, flaking, sorting, milling and brewing (Kabak, 2009). The increase in 
temperature will affect mycotoxin and the concentration of these toxins will decrease 
but it cannot be completely neutralized from food or animal feed because of the high 
temperature needed to completely degraded them (Bullerman and Bianchini, 2007; 
Kam, Bianchini and Bullerman, 2007). Aflatoxin B1 completely degraded at 160° C 
and beyond while Ochratoxin A will stay stable up to 180° C (Raters and Matissek, 
2008).  
2.1.3 The implication of mycotoxins on the genomic DNA 
Aflatoxin B1 and Ochratoxin A considered as the most dangers mycotoxins 
because of their lethal affect to human and animal (El Golli-Bennour et al., 2010). 
Among all mycotoxins, Aflatoxin B1 has the highest carcinogenicity and it could 
pass through mammalian cell membrane where it gets metabolized into unstable 
form and attached to cellular genomic DNA in order to become more stable and 
make different changes (Jarvis & Miller, 2005; Serra, Braga, & Venâncio, 2005; 
Moradi et al., 2015). Aflatoxins B1 considered to be liposoluble compounds in 
nature that can be absorbed at the site of exposure and circulates in the blood stream 
and move across the body (Agag, 2004). Once Aflatoxins B1 are inside the cells, 
they are metabolized by the action of cytochrome P450 and get reduced by to 
aflatoxin-8, 9-epoxide, a highly reactive and unstable form of Aflatoxins B1 which 
requires binding to much more stable molecule such as DNA or protein in order to 
stabilize itself (Eaton & Groopman, 2013; He et al., 2006). Upon binding of the 
unstable aflatoxin-8, 9-epoxide to the DNA molecule, aflatoxin-N7-guanine will be 
formed which was capable of transversion GC to TA mutations. Due to this 
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mutation, cell cycle will be altered by interfering p53 gene expression and the 
production of T-p53 protein which promotes the development of tumors and cancers 
(Yates et al., 2006).  
Ochratoxin A can disturbs cellular physiology according to many researches, 
but its primary effects was reported to be associated with phenylalanine metabolism 
that inhibits enzymes involved in synthesis of the phenylalanine-tRNA complex 
required for cell development (Marquardt & Frohlich, 1992). Cell exposure to 
Ochratoxin A can result in the increase in intracellular reactive oxygen species 
(ROS) which in turn cause a damage to the cellular DNA (Russo et al., 2005; Liu et 
al., 2012). The damage cause by OTA was mainly due to the regulating of FLT3 
signaling (AbdulSalam, Thowfeik and Merino, 2016). FLT3, a tyrosine kinase 
receptor that upon binding to a ligand will dimerized and initiate an 
autophosphorylation that will be blocked by PTPRJ that in turn will leads to the 
activation of AKT, STAT5 pathways and NOX4 transcription. The transcript NOX4 
and CYBA will sustain the signaling pathway responsible for generating O2- which 
will convert to H2O2 by the SOD1 and by the oxidative iteration between PTPRJ and 
PTEN (AbdulSalam, Thowfeik and Merino, 2016). The produced ROS will attack 
DNA molecules and will impose modification in its bases causing DNA breaks, 
inter- and intra-strand crosslinks in addition to DNA-protein crosslinks (Jena, 2012). 
These modification and DNA damage would lead to mutation, cancer and several 
other diseases. Finally, the increase in ROS levels through OTA exposure will lead 
DNA lesions by the means of 8-oxo-7,8-dihydro-guanine, oxazolone, and hydantoins 
(Abdul Salam, Thowfeik and Merino, 2016). In addition to that, Ochratoxin A can 
inhibit ATP production in mitochondria and it enhanced lipid peroxidation (Ringot et 
al., 2006). 
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2.1.4 Mycotoxins carcinogenicity 
Based on the nature of mycotoxins, their effect on human and animals will 
vary. Many mycotoxins are considered to be mutagenic and it was concluded in 
many types of researches that Aflatoxin B1 and Ochratoxin A are strong carcinogens 
(El Golli-Bennour et al., 2010). Aflatoxin B1 considered to  be a well-known 
hepatotoxin (Groopman, Kensler and Wild, 2008) and AB1 outbreaks were linked to 
the incidents of liver cancer in many parts of the world (Yu and Yuan, 2004; Azziz-
Baumgartner et al., 2005; Chen and Zhang, 2011; El-Serag, 2012). Ochratoxin A 
considered as another important mycotoxin because of how it targets the kidney renal 
cells (Marin-Kuan et al., 2007). Ochratoxin A has a strong nephrotoxin ability that 
caused damage in animal and human. Additionally, Ochratoxin A also considered to 
be a very strong liver toxin, highly carcinogenic and it can cause immune 
suppression (Y.-M. Chu et al., 2002).  
2.1.4(a) Aflatoxin B1  
The ubiquitous nature Aflatoxin B1 made them considered as toxic 
metabolites causing serious public health concern and its contamination was 
involved in liver diseases and proven to be hepatotoxic (Kensler et al., 2011). 
Aflatoxin B1 was believed to have a role in causing hepatic and extrahepatic 
carcinogenesis in human by causing  single and double DNA breaks (Gradelet, 
Astorg, Le Bon, Bergès, & Suschetet, 1997). The bioactivation of Aflatoxin B1 will 
produce its epoxide metabolite which will bind to DNA molecules and eventually 
cause a neoplastic transformation of the cells (Massey, Stewart, Daniels, & Liu, 
1995). The activation of Aflatoxin B1 could be accomplished by chemical and 
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enzymatic approach. In the chemical approach, chemical oxidation of 
dimethyldioxirane and enzymatic activation will take place by cytochrome P450 
which will produce a mixture of exo and endo-8,9-epoxides (Iyer et al., 1994). Exo-
8,9-epoxides was known to be the most unstable and most dangerous because it will 
interact with the DNA molecule by attacking the nitrogen atom of the 7
th
 position of 
guanine of the C8 by Sn2 reaction and that will cause trans adduct that lead to the 
formation of a malignant cell (Johnson & Guengerich, 1997; Wilson et al., 1999). 
Endo-8,9-epoxides could not bind to DNA molecules and not considered as 
carcinogenic agent (Iyer et al., 1994). In many cases, the hepatocellular carcinoma 
was somehow related to high levels of AB1 contamination and further investigations 
showed that this toxin cased a mutation in 249th codon of the p53 gene (Hollstein, 
Sidransky, Vogelstein, & Harris, 1991). AB1 will induce a transversion mutation in 
the third position 249th codon of p53 gene and it will cause insertion of serine at the 
249 codon mutant protein (Katiyar et al., 2000). Aflatoxin B1 mutagenic affect can 
cause G→T and C→A transversions between adjacent codons but in less 
frequencies. AB1 transversions mutation in 249
th
 codon in p53 gene and the 
production of mutant TP53 protein was proven to be responsible for hepatocellular 
carcinoma in areas where Aflatoxin B1 contamination in the food was reported (Liu 
and Wu, 2010; Paget, Lechevrel and Sichel, 2011). Another study confirmed the 
carcinogenic effect of AB1 on  liver cells and causing hepatocellular carcinoma in 
Mozambique and Transkei and several parts of Africa and Asia where food 
poisoning with AB1 was reported (Hollstein et al., 1993; Montesano, Hainaut and 
Wild, 1997; Jackson and Groopman, 1999). Another work done by Kelly and 
colleagues studied the effect of AB1 on lung cells and its potential to cause lung 
cancer and the result showed that exo-8,9-epoxides was present in the patients 
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samples collected (Kelly, Eaton, Guengerich, & Coulombe, 1997) suggesting AB1 
involvement in increasing the risk of developing adenocarcinoma of the lung (Divine 
et al., 2001).  
2.1.4(b) Ochratoxin A 
Ochratoxin A nephrocarcinogenicity was discussed extensively and it was 
proven to be carcinogenic in kidney cells in human and animals. In an experiment on 
Male Fischer rats who kidney tumor was discovered within the first three to six 
months (M Marin-Kuan et al., 2006). Ochratoxin A could alter gene expression of 
gene responsible of calcium homeostasis and affect the expression of HNF4α and 
Nrf2 in the kidney (Maricel Marin et al., 2008). Additionally, Ochratoxin A can 
suppress genes responsible for DNA repair in the evens of damage and it was 
reported that it effects the initiation of apoptosis and might lead for the development 
of tumorgenicity (Dörrenhaus et al., 2000; Maricel Marin-Kuan et al., 2008). Finally, 
Ochratoxin A can affect Nrf2-regulated genes in the kidney which was required for 
the chemical detoxication and antioxidant defense mechanism within the cell and in 
the events of cellular oxidative stress (Boesch-Saadatmandi et al., 2008). In a study 
done by Annie and colleagues, Ochratoxin A was found to have a renal 
carcinogenesis effect in rate kidney and it was proven to have genotoxicity by the 
means of covalent DNA adduct formation (Annie Pfohl-Leszkowicz & Manderville, 
2011). When human and animal cells were treated with OTA, single cell death in 
kidney took place (Klarić et al., 2008) and the toxin induce cell proliferation 
inhibition and enlarged cellular nucleus which indicates OTA role in altering cell 
cycle. In addition to that, the results of that experiment indicate the ability of OTA to 
cause increase in lactate dehydrogenase (LDH) activity, increase in Casp3 expression 
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and increase in apoptosis rates. OTA was reported to induce overexpression of 
mitosis regulatory genes such topoisomerase II, surviving, protein kinases Polo-like 
kinase 1, cyclin-dependent kinase 1, cyclins and cyclin-dependent kinase inhibitors 
(Adler et al., 2009). Ochratoxin was proven to be genotoxic carcinogen and cause 
DNA damage due to their ability to oxidase DNA molecules because DNA adducts 
by quinone formation (Pfohl‐ Leszkowicz & Manderville, 2007). In human cells, 
Ochratoxin A can cause phosphorylation of atypical-PKC and that will lead to 
activation of ERK1 and ERK2 and their substrate ELK1, ELK2 and p90RSK 
downstream where PKC and the MEK-ERK MAP-kinase pathways get activated by 
Ochratoxin A and that in turn result in altering cell proliferation, cell survival, 
apoptosis initiation and eventually, renal cancer development (M Marin-Kuan et al., 
2007). Ochratoxin A exposure was also suggested to be one of the environmental 
factors involved in increasing breast cancer risk to male and female rats (Wolff et al., 
1996) and it was also suggested that it can be involved in testicular cancer (Jennings-
Gee et al., 2010).  
2.1.5 Mycotoxins and their implications on human tumor related genes 
There are over 291 cancer and tumor related genes discovered and that 
represents almost 1% of the total genome in human (Futreal et al., 2004; Santarius et 
al., 2010) and researches have conclude the involvement of mycotoxins in regulating 
these genes (Wainfan and Poirier, 1992; Kim et al., 2016; Adam et al., 2017). The 
main effect of mycotoxin on tumor related genes was by the means of inducting 
mutation which would lead to changes in the cell function (Wang and Groopman, 
1999) which eventually could lead to altering cell cycle, inhibition of apoptosis and 
developing cancer (Fink Grernmels, 1999). Another implication of mycotoxins on 
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tumor related genes was by regulating gene expression by interfering the different 
signaling pathways in the cell (Lemmer et al., 1999; Pestka, 2008). Some of the 
genes reported to be targeted by the action of mycotoxins include p53 (Bennett, 
Klich and Mycotoxins, 2003) where the action induce mutation in the gene and 
deactivation of its expression which might result in the development of cancer. In a 
study conducted by Carvajal and colleagues on Keshan disease, the effect of 
mycotoxin was investigated and the result showed that mycotoxins will affect the 
genes that responsible for cell differentiation, development and even apoptosis which 
indicate the role of mycotoxins in the development of  Keshan disease (Carvajal-
Moreno, 2015). 
2.1.6 Aflatoxin B1 and Ochratoxin A and cancer in Malaysia 
Malaysia weather and climate are favorable for the growth and the 
propagation of different fungal strains which will grow on food and produce 
mycotoxins as secondary metabolites. Some of the food found contaminated with 
mycotoxins in Malaysia include cereals, beans, and spices (Afsah-Hejri et al., 2013). 
Mycotoxin exposure in Malaysia was first recorded in 1960 in an incident were AB1 
outbreak caused liver damage to farm animal and in 1988 aflatoxicosis caused the 
death of 13 children in another AB1 outbreak in Perak and the attribute of liver 
cancer due to the exposure to these toxins was reported in many cases in this country 
(Mohd-Redzwan et al., 2013).  
Aflatoxin contamination in Malaysia was very common in food such as 
peanuts, spices, and cereals but surprisingly, the levels of contamination in some 
food exceeds the allowed limit designated by the Malaysian Food Regulation 1985 
(Mohd-Redzwan et al., 2013) and since Malaysians are moderately exposed to 
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Aflatoxins ingestion and since this toxin involvement in liver cancer was proven, 
many studies have reported the involvement in dietary Aflatoxin to liver cancer 
incident around the country. According to the International Agency for Research on 
Cancer (IARC), Aflatoxin ingestion can lead to the development of liver cancer 
(IARC, 1993) and Aflatoxin biomarkers in the biological sample of patients were 
investigated and results showed the presence of AFB1-albumin adduct in the 
hepatocellular cancer patients (Zulhabri et al. 2009). Another study showed that 
AFB1-lysine adduct was present in 97% of 170 subjects in Penang (Leong et al., 
2012). This study was performed on all different ethnics in Malaysia and results 
shows that Chinese were 3.05 and Indians were 2.35 times more likely to have higher 
levels of AFB1-lysine adduct when compare to the Malay (Leong et al., 2012) and it 
was reported by the ministry of health in Malaysia that Chinese are reported to have 
the highest incident of liver cancer in compared to other main ethnicities (National 
Cancer Registry, Malaysia, 2011). Finally, Aflatoxin M1, one of Aflatoxin B1 
metabolite was detected in the urinary sample of 98 subject who consume milk and 
dairy product that can be contaminated with Aflatoxin B1 and the results showed that 
levels of this metabolite was detectable in their samples (Redzwan et al., 2012). The 
presence of Aflatoxin metabolite in the liver cancer patient’s biological samples was 
a strong indicator to the involvement of Aflatoxin B1 contamination and ingestion in 
the development of liver cancer in Malaysia (Mohd-Redzwan et al., 2013). 
Food contamination with Ochratoxin A was common in Malaysia and studies 
has confirm their presence in human food and animal feed and it known for being 
nephrotoxic in human and animals (Jalili, Jinap and Radu, 2010). Some of the food 
that was found to be contaminated with OTA in Malaysia include dried chili (Jalili 
and Jinap, 2012) and it was reported that A total of 65 out of 80 samples were found 
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to have OTA contamination ranging between 0.2 to 101.2 ng/g of the total weight 
and apparently the chilies sold in an open market has a higher chance of getting 
higher concentration of the toxin that the chili sold in the supermarket . In another 
study, an investigation carried out to quantify the levels of OTA in chili powder in 
Malaysia with limit of detection set at 0.10 ng g
−1
 and the results showed mean level, 
range and incidence of positive samples for OTA were 2.21 ng g
−1
, 0.14–20.40 ng 
g
−1
 and 79%, respectively and fifteen positive samples for total for OTA exceeded 
the Malaysian limit which was 5 ng g
−1
 (Ali, Hashim and Shuib, 2015). There are no 
record of the involvement of OTA in causing kidney or other types of cancer in 
Malaysia so far as more attention was given to AB1 but the involvement of OTA in 
kidney cancer and their nephrotoxic ability was studied and proven extensively 
around the world (IARC, 1993; Pfohl-Leszkowicz and Manderville, 2007; el Khoury 
and Atoui, 2010).   
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2.1.7 Aflatoxin B1 and Ochratoxin A involvement in human cancer and their 
possible involvement in Breast cancer  
Aflatoxin B1 and Ochratoxin A were classified as the most dangerous and 
carcinogenic mycotoxins and they were reported to be involved in many cancers. 
Some of the cancers that was associated with AB1 and OTA exposure include liver 
(Gradelet et al., 1998; Lemmer et al., 1999; ALI, 2000; Meki, Abdel-Ghaffar and El-
Gibaly, 2001), kidney (Christoph et al., 2006; Pfohl-Leszkowicz and Manderville, 
2007), urinary track (Pfohl-Leszkowicz and Manderville, 2007; el Khoury and Atoui, 
2010; Sulaiman, Jamaluddin and Sabran, 2018), esophageal (Gelderblom et al., 
1991; Sydenham et al., 1991) and lung (Cui et al., 2015). The mutagenic effect of 
AB1 and OTA on p53 gene was demonstrated in many studies (El Golli-Bennour et 
al., 2010; Kim et al., 2016) and a mutation in p53 was reported in many breast 
cancer cases (Spandidos et al., 1992; Lacroix, Toillon and Leclercq, 2006; Liu et al., 
2007). In addition to that, the mutagenic effect of AB1 and OTA was reported on 
BRCA1 and BRCA2 genes (Bennett and Davis, 2002; Hibi et al., 2013; Pogribny and 
Rusyn, 2013) and a mutation in BRCA1 and BRCA2 was reported in most of breast 
cancer cases (Venkitaraman, 2001; Xu et al., 2001; Gudmundsdottir and Ashworth, 
2006). From the effect of AB1 and OTA on tumor suppressing genes BRCA1, BRCA2 
and p53, a hypothesis can be made which suggest the possibility of AB1 and OTA 
involvement in developing or affecting the development of breast cancer. 
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2.3 Human breast 
Breast defined as the organ projected outside the human body and located on 
the upper chest in both males and females (Falk Dahl et al., 2010). Breast in females 
considered of great importance since it serves as the mammary gland and it’s the 
major component in the process of lactation and it produced milk to feed infants. 
Breasts developed from the embryological tissues in both males and females but is 
has no significant importance in males as it was in females (Kent et al., 1999). The 
development of breast in females starts during puberty where estrogens hormones 
along with human growth hormone result in breast development and maturation. 
During the development of breast, a subcutaneous fat will cover breast tissue and 
will cover a network of ducts that meet at the nipple and breast tissues along with 
subcutaneous fat and ducts shaped the breast and gives it its size (Wiseman and 
Werb, 2002). In the breast, the milk produced in the lobules, the small divisions of 
the breast lobes, a glandular tissue arranged like the petals of a flower. Lobules 
located at the end of the ducts or clusters of alveoli, and it will be stored there and 
excreted in response to hormonal signals. Breast plays and important function during 
pregnancy where it responds the interaction between estrogens, progesterone, and 
prolactin which helps in the completion and the development of lobules in a process 
called lobuloalveolar maturation, to prepare the best for lactating and breast feeding 
(Li et al., 2002). 
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2.3.1 Normal breast cells and tissue  
Figure 2.3: Normal human breast. The source of the picture was retrieved from 
https://www.webmd.com/women/picture-of-the-breasts#1 
 
In the normal breast, breast tissue will cover the chest muscles and they are 
made up from specialized tissue capable of producing milk and these tissues are 
called the glandular tissue, in addition to some fatty tissue. The fat of the breast 
considered to be important in determining the shape and the size of the breast and 
milk usually produced through 15 to 20 sections called as lobes. The milk in the 
normal breast will travels through network small ducts and these ducts come together 
forming larger ducts and milk will exit the body through the nipple on the skin. The 
nipples were surrounded by a dark area called the areola and the connective tissue 
and ligaments in the breast will provide support and form breast chap. In addition to 
that, normal breast will have network of nerve that gives the breast its sensation, it 
also contains many lymph vessels, blood vessels and lymph nodes (Sahiner et al., 
1996; Yan et al., 2006; Lazebnik et al., 2007; Krause et al., 2010) 
